IPO

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

Onex cashes out of Ryan Specialty with a stunning 49% IRR. We dive into the strategy behind the $1.2B exit and what it signals for specialty insurance.

A top care provider changes hands not by choice, but by debt. What does Colisée's fate reveal about the risks of private equity in social care?

With a fresh $62M in funding, WELLSTAR is accelerating its AI and acquisition strategy ahead of a planned 2026 spinout, aiming to rewire Canadian healthcare.

Beyond the $1.2B price tag, Infinity's deal reveals a masterclass in energy M&A, strategic partnerships, and the consolidation of America's shale plays.

Shipping giant Frontline secures a massive capital-raising mandate, signaling bold moves ahead. What does this mean for global energy and investors?

AMC sells its Hycroft Mining stake to gold titan Eric Sprott for $24.1M, ending a curious diversification to double down on its core cinema business.

Swedish innovator SciBase is overhauling its capital structure with a complex warrant buyback. Is this a strategic masterstroke or a necessary defensive play?

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

A landmark government scheme is injecting billions into innovation. Can venture capitalists like Beyond Ventures turn this capital into a tech and health boom?

Whisker's Litter-Robot is now HSA/FSA eligible, a strategic move redefining medical expenses and giving it a major edge in the booming pet tech market.

Abaxx is launching UK wind futures, a critical financial tool to manage renewable energy volatility. Is this the key to de-risking the energy transition?

A key regulatory filing reveals growing investor confidence in the American Axle-Dowlais deal, a move poised to reshape the global automotive supply chain.

A shareholder lawsuit challenges Comerica's $10.9B sale to Fifth Third, citing a rushed process, CEO self-interest, and an undervalued price.

Immatics just secured $125M. This cash infusion is a major bet on its pioneering PRAME-targeted therapies and a key signal for the future of oncology.

Galderma secured stringent EU approval to use its Sculptra biostimulator on the body, targeting a billion-dollar market and setting a new industry benchmark.

TELUS just secured $2.3 billion in a complex debt offering. We decode the move and what it signals about its high-tech ambitions beyond telecom.

SoFi's surprise $1.5 billion stock sale sends shares tumbling. Is this a bold play for market dominance or a sign of fintech's increasing capital hunger?

With a clear FDA path for its breakthrough drug, Praxis is set to disrupt the stagnant, multi-billion-dollar essential tremor market.

Virax secured a $5M runway for its Long COVID diagnostics, but the deal's terms reveal a high-stakes gamble involving significant shareholder dilution.